Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities

January 12, 2024 By The ASCO Post Staff

Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).

Related Content